Table 2.
Selected clinical and laboratory features of patients at baseline.
| Parameters | Group 1 | Group 2 | Group 3 | Group 4 | P value |
|---|---|---|---|---|---|
| AST (IU/L) | 74.1 ± 16.23 | 78.1 ± 10.65 | 75.80 ± 11.47 | 78.10 ± 10.58 | 0.838 |
| ALT (IU/L) | 52.40 ± 14.27 | 54.40 ± 11.62 | 50.10 ± 10.68 | 49.8 ± 8.84 | 0.664 |
| BIL-T (mg/dL) | 2.46 ± 0.90 | 2.72 ± 0.77 | 2.57 ± 0.49 | 2.16 ± 0.71 | 0.412 |
| BIL-D (mg/dL) | 1.11 ± 0.37 | 1.31 ± 0.44 | 1.27 ± 0.44 | 1.21 ± 0.26 | 0.690 |
| Albumin (g/dL) | 2.55 ± 0.37 | 2.75 ± 0.35 | 2.60 ± 0.38 | 2.52 ± 0.34 | 0.970 |
| PT (Sec.) | 28.4 ± 6.70 | 28.0 ± 5.52 | 28.1 ± 4.33 | 27.6 ± 2.07 | 0.980 |
| BUN (mg/dL) | 71.0 ± 20.83 | 71.6 ± 20.94 | 71.4 ± 17.21 | 70.00 ± 11.81 | 0.992 |
| s.Cr (mg/dL) | 1.51 ± 0.35 | 1.48 ± 0.30 | 1.47 ± 0.35 | 1.56 ± 0.31 | 0.820 |
| Sodium (mEq/L) | 124.30 ± 6.85 | 126.5 ± 3.84 | 127.60 ± 5.78 | 128.1 ± 4.58 | 0.286 |
| Hemoglobin (g/dL) | 9.11 ± 0.92 | 9.03 ± 1.16 | 8.71 ± 0.97 | 8.75 ± 0.62 | 0.589 |
| RBCs (106/uL) | 3.22 ± 0.51 | 3.39 ± 0.43 | 3.26 ± 0.41 | 3.31 ± 0.25 | 0.795 |
| WBCs (103/uL) | 8.72 ± 1.70 | 8.95 ± 1.39 | 9.12 ± 1.34 | 9.23 ± 1.35 | 0.875 |
| Platelets (103/uL) | 77.04 ± 17.75 | 77.76 ± 8.75 | 77.76 ± 14.27 | 78.39 ± 11.17 | 0.795 |
| TNF-α (pg/mL) | 128.17 ± 28.63 | 113.37 ± 17.54 | 117.78 ± 22.03 | 115.38 ± 22.21 | 0.49 |
Data presented by mean ± SD; AST: aspartate transaminase; ALT: alanine aminotransferase; BIL-T: total bilirubin; BIL-D: direct bilirubin; PT: prothrombin time; BUN: blood urea nitrogen; s.Cr: serum creatinine; RBCs: red blood cells; WBCs: white blood cells; TNF-α: tumor necrosis factor alpha; pg/mL: picograms per milliliter.